Research Type: Assessment

Multiple Sclerosis: SPMS

Jun 2025 | Assessment

Interventions of Interest For questions please contact Becca Piltch, Program Manager, bpiltch@icer.org. View the Key Stakeholder List.

Retinitis Pigmentosa

Apr 2025 | Assessment

Interventions of Interest For questions please contact Madeline Booth, Program Manager, mbooth@icer.org. View the Key Stakeholder List.

Acute Pain

Feb 2025 | Assessment

Interventions of Interest For questions please contact Temiwunmi Shobanke, Program Manager, tshobanke@icer.org. View the Key Stakeholder List.

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Nov 2024 | Assessment

Interventions of Interest Post-transplant lymphoproliferative disease (PTLD) is a rare, serious, often fatal complication of solid organ transplant (SOT) and allogeneic hematopoietic stem cell transplant (HCST), with only several hundred cases per year reported in the US. The majority of cases of PTLD are associated with the acquisition or reactivation of Epstein-Barr virus (EBV) post-transplant […]

Transthyretin Amyloid Cardiomyopathy

Sep 2024 | Assessment

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year. Final Documents For questions please contact info@icer.org. View […]

Anemia in Myelodysplastic Syndrome

Jul 2024 | Assessment

Interventions of Interest An independent appraisal committee voted that the current evidence is not adequate to demonstrate net health benefits for imetelstat added to best supportive care when compared to best supportive care alone. Imetelstat would meet common thresholds of cost effectiveness if priced between $94,800 to $113,000 per year. The therapy currently priced at […]

Chronic Obstructive Pulmonary Disease

Jun 2024 | Assessment

Interventions of Interest An independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone. ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 to $12,700 per year, and the therapy is priced at $35,400 per year  Final […]

Post-Traumatic Stress Disorder

May 2024 | Assessment

Interventions of Interest Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for MDMA-AP compared to short-term trauma-focused psychotherapies. Click here for “Five Fast Facts on ICER and our PTSD Report.” For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org. […]

Paroxysmal Nocturnal Hemoglobinuria

Feb 2024 | Assessment

Interventions of Interest The independent appraisal committee voted that the current evidence is not adequate to demonstrate a net health benefit for iptacopan over a C5 inhibitor, although use in treatment-experienced patients with clinically significant extravascular hemolysis received more favorable votes. The committee also found that at current pricing, iptacopan represents “low” long-term value for […]

Schizophrenia

Feb 2024 | Assessment

Interventions of Interest: The independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for KarXT compared to generically available aripiprazole. If long-term data confirm KarXT’s benefits and lack of weight gain, it would achieve common thresholds for cost-effectiveness if priced between $16,000 to $20,000 per year. Final Documents […]